Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination of three drugs: - **Heparin** is an anticoagulant that works by potentiate the activity of antithrombin III, thereby inhibiting thrombin and factor Xa, leading to prevention of blood clot formation. - **Piperacillin** is a broad-spectrum penicillin-class antibacterial agent that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. - **Tazobactam** is a beta-lactamase inhibitor that protects piperacillin from enzymatic degradation by beta-lactamase-producing bacteria, thereby extending its antibacterial spectrum. The combination of piperacillin and tazobactam (often marketed as Zosyn) is used for the treatment of various serious infections including intra-abdominal infections, nosocomial pneumonia, skin and skin structure infections, female pelvic infections, and community-acquired pneumonia. Heparin may be co-administered in clinical settings where both infection control and anticoagulation are required; however, this specific triple combination does not have a unique brand or product name. Coadministration requires monitoring due to potential interactions affecting coagulation parameters[1][3][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + piperacillin + tazobactam.